Garetosmab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Garetosmab
- garetosmab
- Garetosmab
- garetosmab [INN]
- GARETOSMAB [JAN]
- GARETOSMAB [USAN]
- garetosmab inn
- garetosmab jan
- garetosmab usan
- regn 2477
- REGN-2477
- regn2477
- REGN2477
- CAS registry numbers
- 2097125-54-5
- ChEMBL ID
- CHEMBL4298176
- FDA ingredient codes (UNII)
- KR9ZSKO5QE
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Inhibin beta A chain inhibitor
- Action type
- Inhibitor
- Target
- Inhibin beta A chain
- Protein identifier
- P08476
Open Targets mechanisms
- Mechanism
- Inhibin beta A chain inhibitor
- Action type
- Inhibitor
- Target
- Inhibin beta A chain
- Condition
- Myositis, Inclusion Body
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007323
- Subject identifier
- D018979
- Condition
- Myositis Ossificans
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007606
- Subject identifier
- D009221
- Condition identifier
- EFO_0007323
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009851
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007606
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007827
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- NCT03188666
- NCT05394116
- NCT03710941
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Glycosylation sites (N)
- Sequence
- Asn-303 $ Asn-303''''
- Component
- Disulfide bridges
- Sequence
- 22-95 $ 22''-95'' $ 23'-89' $ 23'''-89''' $ 135'-195' $ 135'''-195''' $ 140-215' $ 140''-215''' $ 153-209 $ 153''-209'' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-303 $ Asn-303''
- Component
- Light chain: X', X'''
- Type
- Protein
- Sequence
- EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- 61755-012
Related records
Trials (10)
- A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477
- A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
- An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
- Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
- Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
- Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
In development for (2)
- Fibrodysplasia ossificans progressiva Phase 3
- Inclusion body myositis Phase 2
Targets (1)
- INHBA Inhibin beta A chain inhibitor